International Symposium for Digestive Surgery and

Oncology 2016 Winter Meeting of Taiwan Surgical Society of

Gastroenterology and IASGO CME course

2016/12/17 8:00-17:00

NTUH International Convention Center 301 Conference Room

No. 2, Xuzhou Road, Zhongzheng District 100, Taipei City, Taiwan

|  |  |  |  |
| --- | --- | --- | --- |
| 08:00-08:30 | Registration | | |
| 08:30-08:40 | Opening Remarks  Prof. Wei-Jao Chen, Emeritus President of National Taiwan University  Prof. Kyoichi Takaori, Secretary General of IASGO  Prof. Ming-Tsan Lin, President of Taiwan Surgical Society of Gastroenterology | | |
| Time | Topic | Speaker | Moderator |
| 08:40-09:05 | Update and Future of IASGO | Prof. Kyoichi Takaori | 陳敏夫醫師 |
| 09:05-09:30 | Perform an Integrative, Cooperative, Oncologic Research International Institutes | 沈延盛醫師 | 張金堅醫師 |
| 09:30-09:55 | New Breakthrough in Cancer Research | 郭明良醫師 | 李伯皇醫師 |
| 09:55-10:20 | Advance of NTUH in Cancer Treatment Strategy | 林明燦醫師 | 林肇堂醫師 |
| 10:20-10:40 | Coffee Break | | |
| UGI & Pancreas Update | | | |
| 10:40-11:05 | Clinical Trials for Pancreatic Surgery: Experiences from Wakayama Medical University | Prof. Manabu Kawai | 田郁文醫師 |
| 11:05-11:30 | Update Treatment for Gastric Cancer | 陳炯年醫師 | 詹德全醫師 |
| 11:30-11:55 | Advance in Metabolic and Bariatric Surgery | 李威傑醫師 | 詹益銀醫師 |
| 11:55-12:20 | Current status of Pancreatic Neuroendocrine Tumor-Clinical and Research in ShangHai Fudan University | Prof. Wen-Hui Lou | 袁瑞晃醫師 |
| Lunch Symposium | | | |
| 12:45-13:10 | Current Nutrition Therapy for Cancer Surgical Patients | Prof. Kazuhiko Fukatsu | 黃燦龍醫師 |
| 13:10-13:35 | GI Physiology and Support for Cancer Patients | 張子明醫師 | 吳鴻昇醫師 |
| Liver & Biliary Update | | | |
| 13:35-14:00 | Current Treatment Guidelines of HCC & Cholangiocarcinoma | Prof. Masakazu Yamamoto | 胡瑞恆醫師 |
| 14:00-14:25 | Progress in Surgical Management of Cholangiocarcinoma | Prof. Jia-Hong Dong | 沈延盛醫師 |
| 14:25-14:50 | New Direction of Minimally Invasive Approach for HBP Surgery | Prof. Jun Niu | 葉大森醫師 |
| 14:50-15:15 | Modem Minimally Invasive Approach for HBP Surgery in Taiwan | 陳國鋅醫師 | 黃銘德醫師 |
| 15:15-15:35 |  | | |
| Future and Integration | | | |
| 15:35-16:00 | Overview and Future in Cancer Treatment | 郭頌鑫醫師 | 黃清水醫師 |
| 16:00-16:25 | Prevention and Early Treatment for Digestive Cancer | 吳明賢醫師 | 吳誠中醫師 |
| 16:25-16:50 | MINIMALLY Invasive Surgery in HBP Malignancy | Prof. Ho-Seong Han | 雷永耀醫師 |
| 16:50-17:00 | Closing Remarks  Prof. Hong-Nerng Ho, Superintendent, National Taiwan University Hospital  Prof. Ho-Seong Han, Director of Comprehensive Cancer Center, Vice President in Cancer and Neuroscience, Seoul National University Bundang Hospital | | |
| 18:00-21:00 | Gala Dinner | | |

Current Treatment Guideline for Hepatocellular Carcinomas

Masakazu Yamamoto, Shun-ichi Ariizumi, Hiroto Egawa

Department of Surgery

Institute of Gastroenterology

Tokyo Women’s Medical University

There are various staging systems and treatment guidelines for hepatocellular carcinoma (HCC) in the world. However, there is no universal agreement as to which staging system or guideline is the best for patients with HCC. The Barcelona Clinic Liver Cancer (BCLC) staging system is a global standard integrated staging system used world-wide. However, it is appropriate in patients with advanced HCC who are not candidates for surgery. The Japanese Tumor Node Metastasis (TNM) system which consists of three factors; size, number and vascular invasion, is suitable for staging of small HCC. This system was developed on the basis of a national survey by the Liver Cancer Study Group of Japan (LCSGJ). The International Union Against Cancer (UICC) staging system was previously identical to Japan’s TNM system; however, since the 6th version, the UICC classification has been revised to reflect the tumor extension. The 8th version will be released soon. The American Association for the Study of Liver Diseases (AASLD) and the European Association for the Study of the Liver and the European Organization for Research and Treatment of Cancer (EASL-EORTC) have published clinical practice guidelines for liver cancer in 2012. They used BCLC staging system. JCSGJ published a guideline in 2005, followed by a revised edition in 2009 and 2013. The Japan Society of Hematology (JSH) has also published consensus-based clinical practice manual for HCC in 2007, followed by a revised version in 2010 and 2015. There are several differences in treatment algorism among these guidelines. I would like to present the differences, especially differences in strategy for small HCC among treatment guidelines.

**CURRICULUM VITAE**

**Name**: Masakazu Yamamoto, M.D.

**Office**: Department of Surgery, Institute of Gastroenterology

Tokyo Women’s Medical University

**Spatiality**: Hepatobiliary pancreatic surgery

**Positions and appointments**:

    2006-Professor and Chairman, Department of Surgery, Institute of Gastroenterology, Tokyo Women’s Medical University

2010-present Chairman, Institute of Gastroenterology,

**JSHPBS activities**

2016**-** President of Japanese Society Hepato-Pancreato- Biliary Surgery

**IIHPBA activities**

2015- Congress president of A-PHPBA 2017 Yokohama Japan